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Abstract 
Inflammation associated reactive oxygen and nitrogen species (RONs), including 
peroxynitrite (ONOO-) and nitric oxide (NO˙), create base lesions that potentially play a role 
in the toxicity and large-scale genomic rearrangements associated with many malignancies. 
Nevertheless, little is known about the functional role of base excision repair (BER) 
deficiencies following exposure to RONs. Here, we explore the role of XRCC1 in modulating 
the levels of RONs-induced genotoxicity. XRCC1 is a scaffold protein critical for BER for 
which polymorphisms modulate the risk of cancer. We exploited CHO and human 
glioblastoma cell lines engineered to carry varied levels of BER components to study XRCC1. 
Cytotoxicity and SSB-intermediate levels were evaluated following exposure to the ONOO- 
donor, SIN-1, and to gaseous NO˙. XRCC1 null cells are slightly more sensitive to SIN-1 
toxicity. To explore the potential importance of XRCC1 in response to NO˙-induced lesions, 
we used small-scale bioreactors to expose cells to NO˙ and found that XRCC1 does not 
impact genotoxicity in CHO cells, suggesting a minimal role for XRCC1 in response to RONs. 
However, using a molecular beacon assay to measure AAG-mediated lesion removal in vitro, 
we found that XRCC1 facilitates AAG-initiated BER of two key NO˙-induced lesions: 1,N6-
ethenoadenine and hypoxanthine. Furthermore, overexpression of AAG rendered XRCC1 
cells sensitive to NO˙-induced DNA damage and toxicity. These results show that AAG is a 
key glycosylase in response to NO˙ exposure and that the cellular and functional impact of 
XRCC1 depends upon the level of AAG. These studies are some of the first to assess the 
functional role of XRCC1 in response to NO˙, and demonstrate the importance of BER 
balance when considering the impact of XRCC1 polymorphisms in response to RONs. 
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1.0 Introduction 
The association between chronic inflammation and cancer is well established, with 
upwards of 15% of all malignancies associated with chronic inflammation [1-5]. Of particular 
interest is the role played by reactive oxygen and nitrogen species (RONs) in the initiation 
and promotion of malignancy. During inflammatory states, neutrophils and macrophages 
become activated and release genotoxic RONs, including nitric oxide (NO˙) and superoxide 
[6, 7].  These RONs are not only toxic to target cells, but they also induce collateral damage 
on neighboring tissue.  We hypothesize that DNA damage caused by NO˙ and NO˙-derived 
chemicals can cause genotoxicity and genomic instability that initiates and promotes 
malignancy. 
NO˙ is an important signaling molecule at lower concentrations [8-10], but can be 
genotoxic at higher concentrations [11, 12]. Indeed, via its reactions with superoxide and 
oxygen to form ONOO- and nitrous anhydride (N2O3) respectively, NO˙ has been shown to 
induce numerous DNA lesions both in vitro [12, 13] and in vivo [14]. For example, ONOO- 
can oxidize guanine, making 8-nitroguanine [15], which can spontaneously depurinate 
leaving an abasic site [6, 15]. Furthermore, ONOO- can make direct DNA single strand breaks 
(SSBs) or damage DNA bases in the presence of CO2, via the action of 
nitrosoperoxycarbonate [16, 17]. In contrast, N2O3 primarily creates base deamination 
products; converting guanine to xanthine, adenine to hypoxanthine and cytosine to uracil, 
all of which induce transition mutations [13]. Additionally, RONs can cause lipid 
peroxidation, creating secondary metabolites that can subsequently alkylate DNA and 
create mutagenic alkylation lesions such as 1,N6-ethenoadenine (εA) [18, 19]. The alkylation 
lesion εA blocks replicative polymerases [20]; is mutagenic causing A:T→G:C transitions, 
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A:T→T:A transversions [21, 22]; and is associated with the signature p53 and Kras mutations 
observed in rat and human liver cancers following exposure to vinyl chloride [23, 24].  
The DNA lesions resulting from exposure to RONs can promote a number of 
deleterious phenotypes including toxicity [25, 26], elevated DNA double strand breaks 
(DSBs) [27], point mutations [14, 28] and large-scale genomic rearrangements [29].  
Consequently, the repair of RON-mediated DNA damage may be an important mechanism 
for mitigating the toxic and tumorigenic effects of these lesions. Indeed, a recent study 
shows that mice deficient in alkyl adenine DNA glycosylase (AAG), the DNA glycosylase that 
repairs NO˙-induced εA, have an increased susceptibility to inflammation-induced cancer 
[30]. Thus, an individual’s capacity to repair inflammation-mediated DNA lesions may 
represent a hitherto poorly defined risk factor for inflammation-mediated malignancy [30-
34].  
 In mammalian cells, base excision repair (BER) is responsible for repairing many of 
the inflammation-mediated lesions described above. Briefly, this pathway consists of five, 
enzyme-catalyzed steps: lesion excision, strand scission, gap tailoring, DNA synthesis and 
ligation. For a detailed review of BER, the authors refer the reader elsewhere [31, 35-38]. 
Importantly all five enzymatic steps in the BER pathway are putatively facilitated by the x-
ray repair cross-complementing group 1 (XRCC1) protein. Indeed, XRCC1 is a scaffold protein 
that, although lacking its own enzymatic activity, facilitates the enzymatic roles of numerous 
other BER pathway proteins. For example AAG, the DNA glycosylase that carries out excision 
of 3-methyl adenine (3me-A) [39], hypoxanthine (Hx) [39], εA [30] and other alkylpurines 
[40], has been shown to be physically and functionally associated with XRCC1 [39]. In 
addition, XRCC1 interacts with APE1, PARP1 and DNA polymerase ß (Polß) [35, 41, 42]. As a 
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consequence of its central role in base excision repair, XRCC1 deficient cells are deficient in 
the repair of alkylation [43, 44] and ionizing radiation-induced [45-47] DNA damage. 
Furthermore, XRCC1 deficient cells are acutely sensitive to killing by alkylating agents, such 
as methyl methane sulfonate (MMS) [48, 49]. Additionally, XRCC1 deficient cells have higher 
baseline and post-MMS-exposure sister chromatid exchanges (SCEs) [50, 51], which are a 
measure of large-scale genomic rearrangements and thus represent a genomic instability 
mutator phenotype. Thus, despite having no enzymatic activity, XRCC1’s ability to act as a 
scaffold that accelerates BER clearly has many important biological effects.  
 Inflammatory RONs, such as NO˙, are highly genotoxic. Nevertheless, very little is 
known about the susceptibility of XRCC1 deficient cells following exposure to inflammatory 
genotoxins. Previous studies have shown that XRCC1 deficient Chinese hamster ovary (CHO) 
cells have elevated levels of SCEs following exposure to NO˙ [51], suggesting an important 
role for XRCC1 during inflammation. Furthermore, XRCC1 deficient mouse [48] and CHO [52] 
cells are moderately sensitive to hydrogen peroxide [53]. Collectively, these findings suggest 
that XRCC1 may be important in the repair of RON-mediated DNA damage and may 
modulate toxicity and cancer risk. Indeed, various polymorphic variants in XRCC1 have been 
shown to be either positively [54] or negatively [55-57] associated with various 
inflammation-associated malignancies. These findings underscore the importance of 
defining the role of XRCC1 in response to inflammatory genotoxins, both for cancer risk 
assessment and for therapeutic intervention. 
Here, we have analyzed the role of XRCC1 in the context of two cell types. In CHO 
cells, we found that XRCC1 prevents SIN1 and MMS-induced toxicity, but does not impact 
NO˙-induced toxicity. However, using a molecular beacon assay with extracts from human 
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glioblastoma cells to measure glycosylase-mediated base lesion removal, we found that 
XRCC1 facilitates AAG-initiated BER of two NO˙-induced DNA base lesions, εA and 
hypoxanthine. Furthermore, in the human glioblastoma cell lines, BER imbalance mediated 
by overexpression of AAG sensitized cells to NO˙-induced toxicity and DNA damage as well 
as the response of these cells to MMS. Together these data indicate that AAG is an 
important DNA glycosylase in the response to NO˙-exposure, and that the role of XRCC1 
depends upon the level of AAG. Therefore, the impact of an XRCC1 deficiency is context 
dependent, wherein under conditions of BER imbalance, there is increased susceptibility to 
NO˙-induced genomic instability.  
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2.0. Materials and Methods 
2.1 Cells and Cell Culture 
AA8 and EM9 CHO cells were obtained from ATCC (Manassas, VA) and the human 
complemented EM9 cells were engineered, and kindly provided by the lab of Larry 
Thompson [46]. CHO cells were cultured in 10% FBS (Atlanta Biologics, Lawrenceville, GA) in 
DMEM (Cat#11965, Invitrogen, Carlsbad, CA) and penicillin/streptomycin (100U/ml; 
100µg/ml) (Sigma, St. Louis, MO). CHO cells were cultured in 150mm dishes (Falcon, BD) and 
were kept growing exponentially, being passaged approximately once every three days. Cell 
passaging was conducted by aspirating media, rinsing in warm PBS and treating cells with 
warm trypsin (Invitrogen, Carlsbad, CA) for 5-10 min, quenching with 10mL media and then 
transferring 1mL of the resultant cell suspension to 30 mL media. 
 Engineering of glioblastoma LN428 cells has previously been published [58, 59]. The 
cell line LN428 (herein referred to as LN428WT) is an established glioblastoma derived cell 
line with mutations in p53 and deletions in p14ARF and p16 and is WT for PTEN. Briefly, 
human AAG expressing cells were generated by transfection of the AAG expression plasmid 
pRS1422 using FuGene 6 transfection reagent (Roche, Indianapolis, IN) according to the 
manufacturer's protocol. Transfected cell lines were cultured in G418 for two weeks, and 
individual clones stably expressing human AAG were selected. The lentiviral shuttle vectors 
(control: pLKO.1-puro-turbo green fluorescent protein [GFP]) were purchased from Sigma, 
as was the XRCC1 shRNA shuttle vector (Gene ID: NM_006297, Clone ID: NM_006297.1-
1489s1c1, Target sequence: CCAGTGCTCCAGGAAGATATA), via the UPCI Lentiviral facility. 
Lentiviral particles were generated by co-transfection of four plasmids [pLKO.1-puro-
TurboGFP or pLKO.1-puro-XRCC1shRNA together with pMD2.g(VSVG), pVSV-REV and 
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pMDLg/pRRE] into 293-FT cells using FuGene 6 Transfection Reagent (Roche, Indianapolis, 
IN), as described previously [58]. Forty-eight hours after transfection, lentivirus-containing 
supernatant was collected and passed through 0.45 µM filters to isolate the viral particles. 
Lentiviral transduction was performed as described earlier [58].  The LN428WT cells were 
cultured in alpha MEM (Invitrogen, Carlsbad, CA), 10% fetal bovine serum (Atlanta Biologics, 
Lawrenceville, GA), antibiotic/antimycotic (Sigma), gentamicin, L-glutamine (Sigma). The 
XRCC1-KD and the LN428/GFP glioblastoma cell lines were cultured in the same media as 
the LN428WT cells described above supplemented with 1 µg/mL puromycin (Sigma). The 
AAGOE glioblastoma cell line (LN428 cells modified for elevated expression of AAG) was 
cultured in the same media as the LN428WT cells and supplemented with 600 µg/mL 
Geneticin (InVitrogen) and the AAGOE/XRCC1-KD glioblastoma cell line (LN428 cells 
modified for elevated expression of AAG and loss of XRCC1 expression) was cultured in the 
same media as the LN428WT cells and supplemented with 600µg/mL Geneticin (InVitrogen) 
plus 1 µg/mL puromycin (Sigma). 
 
2.2 Cell extract preparation and Immunoblot 
             CHO whole cell extracts were prepared using RIPA buffer according to the 
manufacturer’s instructions (Pierce, Rockford, IL). Protein concentration assessment in cell 
extracts was done by BCA quantification (Pierce, Rockford, IL) according to the 
manufacturer’s instructions. Volumes containing 20-100 µg of protein were loaded into a 
precast 4-20% gradient Tris-HCl gel (BioRad, Hercules, CA). Protein was transferred onto a 
nitrocellulose membrane and XRCC1 protein was probed using a rabbit polyclonal primary 
antibody against XRCC1 (Abcam, Cambridge, MA) and an HRP-conjugated secondary goat 
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antibody against rabbit IgG. For the loading control a rabbit monoclonal antibody (Cell 
Signaling, Beverly, MA) against β-actin was used. LN428 nuclear extracts were prepared and 
protein concentrations were determined as described previously [58]. 20 µg of protein was 
loaded on a precast 4–20% Tris-glycine gel (Invitrogen) or 25 mg of protein was loaded onto 
a precast 4–20% Mini-PROTEAN TGX gel (Bio-Rad). For the analysis of the human 
glioblastoma cell lines, the following primary antibodies were used in the immunoblot 
assays: anti-human MPG (Mab; clone 506-3D) [58]; anti PCNA (Santa Cruz Biotechnology, 
Santa Cruz, CA) and anti-XRCC1 (Bethyl Labs; Montgomery, TX). 
 
2.3. CHO MMS and SIN-1 Exposures for Comet Assay 
Log phase CHO cells were rinsed with warm PBS and passaged as described above. 
Approximately 24 hours later, cells were trypsinized, counted and re-suspended in 1% low 
melting point (LMP) agarose (Invitrogen, Carlsbad, CA) at 37°C at a density of 2.5×105 
cells/mL. A volume of 500µL (1.25×105 cells) of gel containing re-suspended cells was then 
pipeted onto 37°C pre-warmed, agarose-precoated glass slides and cover-slipped. The cells 
were allowed to settle onto the slides for 10 minutes and were then moved to 4°C to allow 
the gel to solidify. Coverslips were removed and the cells were exposed to either MMS or 
SIN-1 at the specified concentrations in PBS (Invitrogen, Carlsbad, CA). For the repair 
experiments, following exposure, the slides were rinsed with PBS and were transferred to 
CHO media for the specified period of time before being lysed for the alkaline comet assay, 
as described below (Section 2.6).  
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To investigate the DNA repair capacity of CHO cell lines exposed to MMS, the 
CometChip, a high throughput version of the comet assay, was used as described by us 
previously [60]. This approach enabled four cell lines (AA8, EM9, H9T3-6-3, H9T3-7-1) to be 
evaluated simultaneously in a standard 96-well format. Briefly, at least 10,000 cells were 
added to each well and allowed to settle into arrayed microwells by gravity. Excess cells 
were aspirated after 15 minutes and the arrayed cells were encapsulated in a layer of 1% 
low melting point agarose. After exposure to the specified dose of MMS, the wells were 
rinsed with PBS and replenished with fresh growth medium for the specified period of time 
before lysis was conducted for the alkaline comet assay.  
 
2.4 CHO and Glioblastoma NO˙ Exposures 
For NO˙ exposures, 1×106 CHO or glioblastoma cells were seeded in media into 
60mm tissue culture dishes (BD Falcon, Franklin Lakes, NJ). Approximately 24 hours later, 
dishes were secured to the bottom of a 100mL bioreactor and exposed to gases for 
specified periods of time, as previously described [29, 61, 62]. Following exposure, a sample 
of media was taken for nitrite quantification and the cells were trypsinized, counted, and 
analyzed for clonogenic survival and DNA damage using the alkaline comet assay. 
 
2.5 Clonogenic Survival Assay 
Clonogenic survival assay was conducted using standard protocols. Briefly, CHO and 
glioblastoma cells were seeded and approximately 24 hours later, cells were exposed to SIN-
1 or MMS for 30min at 37°C. The cells were then rinsed with PBS and incubated in media for 
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10-14 days to form colonies. The colonies were then fixed in 1:1 Methanol:PBS and stained 
with 0.5% crystal violet in 1:1 methanol:PBS for 10min. Colonies were rinsed with de-ionized 
water, allowed to dry and were then counted. P values were calculated by student’s t-test 
on the mean of at least three replicate experiments. 
 
2.6 Alkaline Comet Assay 
To measure the accumulation of base excision repair intermediates following 
exposure to a given genotoxin, a modified version of the alkali comet assay (single cell gel 
electrophoresis) was employed [63]. Briefly, cells immobilized in 1% agarose were lysed for 
at least one hour in lysis buffer containing 2.5 M NaCl, 100 mM Na2EDTA, and 10 mM tris 
and 1% triton X-100 at pH 10. Following lysis, cells in the gel are held in electrophoresis 
buffer (0.3 M NaOH, 1 mM Na2EDTA) for 40 minutes for alkali unwinding. Following the 
alkali unwinding incubation, electrophoresis was performed at 1V/cm, 300mA for 30 min. 
Slides were neutralized in 0.4 M tris, before staining with 500 µg/mL ethidium bromide. 
Analysis was carried out by Metafer v.3.6.7 (Metasystems, Waltham, MA). At least 100 
nucleoids per condition were analyzed and the median calculated. Each experiment was 
replicated at least 3 times and the mean of all replicates plotted. P values were calculated 
by student’s t-test. To measure the accumulation of base excision repair intermediates 
following MMS exposure, a single high throughput comet gel was used to simultaneously 
assess all cell types and repair time points. After conducting the standard comet assay 
protocol described above, analysis was carried out using automated software described 
previously [60].  
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2.7 AAG-specific Molecular Beacon Assay 
Oligodeoxyribonucleotides were designed, as we have described [59] to form a 
stem-loop structure with 13 nucleotides in the loop and 15 base pairs in the stem.  
Carboxyfluorescein (6-Fam) is a fluorescent molecule that is quenched by Dabcyl in a non-
fluorescent manner via Fӧrster Resonance Energy Transfer (FRET) [64, 65].  
Oligodeoxyribonucleotides were purchased from Integrated DNA Technologies (Coralville, 
USA):  
FD-Con, 6-FAM-dGCACTATTGAATTGACACGCCATGTCGATCAATTCAATAGTGC-Dabcyl, where 
6-FAM is carboxyfluorescein and Dabcyl is 4-(4’-dimethylaminophenylazo) benzoic acid;  
FD-MPG1, 6-FAM-dGCACTXTTGAATTGACACGCCATGTCGATCAATTCAATAGTGC-Dabcyl, 
where X is 1,N6-ethenoadenine (εA);  
FD-MPG2, 6-FAM-dGCACTXTTGAATTGACACGCCATGTCGATCAATTCAATAGTGC-Dabcyl, 
where X is hypoxanthine (Hx); 
FD-THF,     6-FAM-dGCACTXTTGAATTGACACGCCATGTCGATCAATTCAATAGTGC-Dabcyl, 
where X is terahydrofuran (THF), an abasic site analog [66]. 
 When the DNA is in a stem-loop structure, the 6-FAM at the 5’ end and the Dabcyl at 
the 3’ end are brought into close proximity, enabling efficient quenching of 6-FAM by 
Dabcyl.  If the lesion (εA or Hx) is removed by AAG and the DNA backbone is hydrolyzed by 
APE1 (THF), the 6-FAM-containing oligonucleotide (4 bases in length) will dissociate from 
the hairpin at 37˚C and the 6-FAM dissociation from the DNA hairpin prevents the 
quenching by Dabcyl.  The increase in 6-FAM-mediated fluorescence is proportional to the 
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amount of the lesion removed.  Any increase in fluorescence in control beacon with a 
normal adenine would be the result of non-specific cleavage of the DNA backbone.   
Nuclear protein extracts were prepared as previously described [59].  Approximately 
500 μL of nuclear protein extracts were dialyzed twice using the Slide-A-Lyzer Dialysis 
Cassette with a 7,000 molecular weight cut-off (Pierce; Rockford, IL).  The samples were 
dialyzed 2x for 90 min each at 4°C in the following buffer: 50 mM Hepes pH7.5, 100 mM KCl, 
0.5 mM EDTA, 20% Glycerol and 1 mM DTT. Reactions were performed using 10 μg of 
dialyzed protein extract and beacon substrate (final conc = 40 nM) in the following buffer: 
25 mM HEPES-KOH pH7.8, 150 mM KCl, 0.5 mM EDTA, 1% Glycerol, 0.5 mM DTT. 
Fluorescence was measured, every 20 seconds for 60 minutes, using a StepOnePlus real-
time PCR system and expressed as arbitrary units (AU).  The fluorescence data was then 
analyzed as we have described [59]. Briefly, background fluorescence (from incubation of 
the beacon alone) was eliminated by subtracting the fluorescence values of a control well 
containing no protein extract from all wells. The fluorescence value of the 5-minute time 
point was selected as the zero value for each well.   We subtracted this value from all other 
time points in that well so all graphs begin from zero AU and 5 minutes after initiating the 
reaction.  Five minutes was selected as the point from which to begin comparisons because 
time points earlier than four minutes contained variations in absolute fluorescence 
measurements independent of molecular beacon and cell line (not shown). The mean of 
three separate trials was plotted with error bars representing the standard error of the 
mean. The mean fluorescence values and the values for the standard error of the mean for 
each are listed in Dataset S1 in the Supplement.  
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2.8 MMS-induced Cytotoxicity Assay in Glioblastoma Cells 
MMS-induced cytotoxicity was determined by an MTS assay, a modified MTT assay 
as described previously [58]. Briefly, cells (LN428WT, XRCC1-KD, AAGOE and AAGOE/XRCC1-
KD) were seeded in 96-well dishes at 2000 cells/well.  After 24 hours, cells were exposed to 
serial dilutions of MMS (6 wells per dose) in growth media for 4 hours at 37˚C.  MMS-
containing medium was replaced with fresh medium and the plates were incubated at 37˚C 
for an additional 48 hours at which point the total cell number was determined by a 
modified MTT assay (MTS; Promega) [67]. Metabolically active cells were quantified by the 
bioreduction of the MTS tetrazolium compound by recording absorbance at 490 nm using a 
microplate reader. Results were calculated from the average of three separate experiments 
and are reported as the % of treated cells relative to the cells in control wells (% Control). 
 
2.9 Quantitative RT-PCR Analysis 
 Validation of shRNA-mediated reduction of XRCC1 expression was initially 
determined by quantitative RT-PCR (qRT-PCR) using an Applied Biosystems StepOnePlus 
system. Briefly, 80,000 cells were lysed and reverse transcribed using the Applied 
Biosystems Taqman® Gene Expression Cells-to-CT™ Kit.  Each sample was analyzed in 
triplicate and the results are an average of all three analyses. Analysis of mRNA expression 
was conducted as per the manufacturer (∆∆CT method) using Applied Biosystems TaqMan® 
Gene Expression Assays (XRCC1: Hs00959834_m1) and normalized to the expression of 
human ß-actin (part #4333762T). 
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3.0. Results and Discussion 
3.1. Role of XRCC1 in response to NO˙ and ONOO- exposure in CHO cells 
Reactive oxygen and nitrogen species released by activated immune cells can cause 
myriad DNA lesions. Among these potentially deleterious reactive species are NO˙ and 
superoxide, which can combine to form ONOO-, a dominant reactive nitrogen species 
formed under physiological conditions [6]. Our first objective was therefore to investigate 
whether cells deficient in XRCC1 are susceptible to ONOO- and NO˙.  
To learn about the role of XRCC1 in response to NO˙ and ONOO-, we exploited EM9 
CHO cells, which are effectively null for XRCC1 as they carry a frameshift mutation that 
results in expression of only a third of the XRCC1 protein [68] (Fig. 1A). The EM9 mutant 
cells were initially isolated from their parental AA8 CHO cell line by a generalized mutant 
screen for sensitivity to DNA damaging agents and are sensitive to killing by ethyl methane 
sulfonate (EMS), MMS and ionizing radiation [45, 47, 49]. Additionally, EM9 cells display 
defective base excision repair [49, 69] and have elevated frequency of baseline [49, 70] and 
post-genotoxin exposure sister chromatid exchanges (SCEs).  As controls, we used the 
parental AA8 CHO cell line and XRCC1-deficient EM9 cells complemented with the human 
XRCC1 cDNA (H9T3-6-3 and H9T3-7-1 cells, gift of L. Thompson) (Fig. 1A)[46].  
Following exposure to SIN-1, gaseous NO˙ or MMS, CHO cells were assessed for 
survival via a clonogenic survival assay. XRCC1 deficient cells have previously been 
demonstrated to be deficient in the repair methylation damage, and are therefore highly 
sensitive to MMS [43, 44, 46, 49, 69, 71]. We therefore exposed cells to MMS as a reference 
against which to benchmark the effects of exposure to inflammatory RONs.  As previously 
established [44, 46, 49], XRCC1 deficient CHO EM9 cells were significantly more susceptible 
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to MMS exposure than XRCC1 WT AA8 cells and human XRCC1-complemented H9T3-6-3 and 
H9T3-7-1 cells (Fig. 1B). In contrast, XRCC1 deficient cells were only slightly more sensitive 
to SIN-1 exposure (p< 0.05 for doses over 5mM) when compared to WT CHO cells or human 
XRCC1-complemented CHO cells (Fig.1C). These results are consistent with studies showing 
that XRCC1 deficient cells are mildly sensitive to oxidizing agents [48].  In contrast to SIN-1, 
XRCC1 null EM9 cells were no more sensitive than WT cells to NO˙ exposure (Fig. 1D), even 
at doses that are toxic to WT cells.  
The observation that XRCC1 cells have a slight, yet significant increase in sensitivity 
to SIN-1 and not to NO˙ is surprising and may be due to the difference in the spectrum of 
lesions made by SIN-1 versus NO˙.  While SIN-1 and NO˙ may make many of the same lesions 
via ONOO-, including direct DNA SSBs [16, 72] and oxidized base lesions including 8-oxo-7, 8-
dihydro-2´-deoxyguanosine [73], 8-nitro-2´-deoxyguanosine [15, 17] and 5-guanidino-4-
nitroimidazole [74], NO˙ exposure can result in other chemistries. For example, NO˙ can 
cause base deamination via the action of nitrous anhydride (N2O3). Deamination of DNA by 
nitrous anhydride can form xanthine and hypoxanthine from guanine and adenine, 
respectively. While the lesions formed by oxidative damage are generally removed by 
bifunctional glycosylases, the deamination products are generally removed by 
monofunctional glycosylases. Therefore, the uncleaved abasic sites formed after removal of 
NO˙-induced deamination products may be more readily tolerated by XRCC1 deficient cells, 
compared to the cleaved abasic sites formed at sites of ONOO-- induced oxidative lesions (or 
the directly induced SSBs) [75-77]. 
As an alternative approach for evaluating the biological role of XRCC1 in response to 
RONs, we investigated XRCC1’s impact on BER capacity following RON-induced DNA 
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damage. To assess BER, we used the alkaline single cell gel electrophoresis (comet assay) 
using both the standard comet assay protocol and the high throughput format described by 
us previously [60]. The alkaline comet assay is a well established, gel-electrophoresis based 
assay that has been used to measure DNA SSBs, apurinic/apyrimidinic (AP) sites and alkali-
labile base lesions in single cells [60, 63, 78, 79]. The assay can thus be used to measure the 
levels of DNA base excision repair intermediates, following exposure to inflammatory RONs. 
We found that XRCC1 deficient EM9 cells trend towards a greater accumulation of base 
excision repair intermediates compared to WT cells, as the cells are exposed to increasing 
concentrations of MMS (Fig. 2A), which is consistent with previous studies [41, 43, 44, 48, 
71]. XRCC1 deficient EM9 cells also clearly show slower repair kinetics, as expected (Fig. 2C). 
In contrast to MMS, XRCC1 deficient cells displayed equivalent levels of BER intermediates 
as WT cells following exposure to increasing concentrations of SIN-1 (Fig. 2B) and the XRCC1 
null EM9 cells repair SIN-1-induced BER-intermediates with the same efficiency as the AA8 
WT cells (Fig. 2D). These data indicate that, at least in CHO cells, XRCC1 does not play a 
significant role in the repair of SIN-1-induced DNA damage, as assessed by the alkali comet 
assay.  
To explore the possibility that XRCC1 modulates repair of NO˙-induced DNA damage, 
we used the comet assay to assess the BER intermediate levels in EM9 and AA8 CHO cells 
following exposure to increasing durations of exposure to NO˙.  A previously described 
bioreactor system was used to expose cells to NO˙ [61, 62]. Briefly, cells were exposed to 
gaseous NO˙ at a steady state concentration (~2µM for 10% NO˙ and ~11µM for 100% NO˙) 
for varying lengths of time to deliver increasing cumulative doses, typically expressed as 
µM/min, but expressed here as duration of exposure for simplicity. For comparison, and to 
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control for any results due to the chronicity of exposure to NO˙, conditions were developed 
for chronic MMS exposure that yield a comparable impact on the levels of DNA damage (as 
revealed by the comet assay). We found that the XRCC1 deficient EM9 cells displayed 
elevated levels of BER-intermediates following increasing duration of exposure to MMS (Fig. 
3A), which is consistent with their slower repair kinetics (Fig. 2C). In contrast to MMS 
exposure, rather than seeing increased levels of BER intermediates in the XRCC1 deficient 
cells, following increasing duration of exposure to NO˙ we observed that the WT AA8 cells 
showed higher levels of NO˙-induced BER intermediates (Fig. 3B).  
The observation that the XRCC1 WT cells have higher levels of BER intermediates 
than the XRCC1 null EM9 cells may at first glance seem anomalous. However, since the 
comet assay detects AP sites and frank DNA SSBs, the comet assay effectively detects DNA 
species in-between the glycosylase step and the ligation step of the BER pathway. 
Therefore, the increase in BER intermediates in WT cells relative to the XRCC1 deficient cells 
following exposure to NO˙ may reflect XRCC1-facilitated removal of NO˙-induced base 
damage. Since SIN-1 exposure did not result in the same BER-intermediate dynamics as 
those observed following exposure to NO˙, one could speculate that XRCC1 may modulate 
the function of a glycosylase (e.g., AAG) that acts specifically on NO˙-induced DNA damage 
and not SIN-1-induced damage, i.e. deamination products like xanthine and hypoxanthine. 
Indeed, other groups have shown that AAG can excise hypoxanthine [80-82], and that 
XRCC1 can enhance this activity [39]. We therefore set out to more directly explore the 
impact of XRCC1 on AAG-mediated excision of NO˙-mediated DNA damage. 
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3.2 Role of XRCC1/ AAG interaction in human (glioblastoma LN428) cell extracts 
Two key mutagenic lesions created by NO˙ and excised by AAG are hypoxanthine 
(Hx) and 1,N6-ethenoadenine (εA). Hx is the deamination product of adenine that is formed 
by NO˙ via the nitrosative action of nitrous anhydride (N2O3)—an auto-oxidation product of 
the reaction between NO˙ and molecular oxygen [6]. Hx mispairs with cytosine, causing A:T 
→ G:C transition mutations. In contrast, εA can mispair with adenine, guanine or cytosine 
[83] and is a DNA damage-mediated product of RON-derived lipid peroxidation [18, 84, 85]. 
Furthermore, εA inhibits DNA replication [86] and is thus a toxic base lesion [87]. We 
therefore investigated whether, and to what extent, XRCC1 facilitates AAG-initiated BER of 
Hx and εA DNA lesions. To do this, we used LN428 glioblastoma cells that were WT 
(LN428WT) or that were engineered to be deficient in XRCC1 via lentiviral-mediated shRNA 
knockdown (XRCC1-KD). In addition, we used these same cells engineered to over-express 
AAG (AAGOE and AAGOE/XRCC1-KD), and cells engineered to express GFP (GFP) as a control 
for the exogenous constructs in the other cells. As shown, the LN428WT cells express a very 
low, undetectable level of AAG but express measurable levels of XRCC1, as determined by 
immunoblot analysis (Fig. 4A). To compare the expression levels of XRCC1 and AAG among 
the four cell lines, the immunoblot was scanned and quantified using NIH Image J and the 
associated analysis software package, normalizing the expression across the four cell lines to 
the AAGOE cells and to the expression of PCNA within each sample. As indicated in the plot 
of relative protein expression (Fig. 4B), the AAG expression levels are very similar when 
comparing the AAGOE and AAGOE/XRCC1-KD cells. Similarly, the expression of XRCC1 is 
similar when comparing the LN428WT and AAGOE cells. Importantly, no expression of 
XRCC1 was detected in the XRCC1-KD and AAGOE/XRCC1-KD cells. 
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To measure AAG-dependent DNA glycosylase activity or APE1-dependent abasic site 
hydrolysis, we developed a fluorescence-based molecular beacon excision assay to measure 
the efficiency with which AAG can excise specific base lesions (Hx or εA) or that APE1 can 
hydrolyze an abasic-site analog (Tetrahydrofuran, THF) in real-time, in vitro, essentially as 
we have described [59]. We assessed the ability of cell extracts from LN428WT, XRCC1-KD, 
AAGOE and AAGOE/XRCC1-KD cells to excise εA, Hx or THF [59]. We observed minimal 
fluorescence when extracts were incubated with a control molecular beacon that contained 
no lesion (Fig. 4C). Since the signal (fluorescence) is generated following base lesion removal 
and abasic site hydrolysis by APE1, we also tested each lysate using a THF beacon to ensure 
that all four lysates could similarly cleave an abasic site. As expected, a similar increase in 
fluorescence was observed by all four of the cell extracts when evaluated for APE1 activity 
using the THF beacon (Fig. 4D). It should be noted that we did not observe any difference in 
activity between the XRCC1 expressing cells (LN428WT and AAGOE) and the XRCC1-KD cells 
(XRCC1-KD and AAGOE/XRCC1-KD), indicating that cleavage of the AP site by APE1 is not 
influenced by XRCC1. An earlier report using purified enzymes suggested that XRCC1 
stimulates APE1-mediated 3’-5’ exonuclease activity but it is not likely that this activity of 
APE1 is measured in this assay [88]. However, our data is in contrast to an earlier report 
suggesting that XRCC1 and APE1 interact and that XRCC1 stimulates APE1 activity [42]. 
Clearly, such an XRCC1-dependent stimulation of APE1 activity is not observed here, at least 
for the hydrolysis of the THF abasic site analog.  
Conversely, a molecular beacon containing hypoxanthine (Hx) resulted in a time-
dependent increase in fluorescence when incubated with extracts from LN428WT, XRCC1-
KD, AAGOE and AAGOE/XRCC1-KD cells, which is indicative of base release by the AAG 
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glycosylase and cleavage of the resulting AP site (Fig.4E). As expected, cells over-expressing 
AAG (AAGOE) yielded the highest increase in fluorescence, which is consistent with these 
cells being the most efficient at excising the Hx lesion. However, when XRCC1 expression is 
knocked down in the AAGOE cells (AAGOE/XRCC1-KD), there is a decrease in the observed 
fluorescence (Fig. 4E). The observed 25% reduction in glycosylase activity in the XRCC1 
deficient cells (when measured at 40 min) indicates that XRCC1 facilitates AAG excision of 
Hx, which is consistent with a previous report using purified recombinant proteins [39]. In 
contrast to the cells overexpressing AAG, the molecular beacon assay yields very little signal 
for the LN428WT or the XRCC1-KD cell extracts. The nominal increase in fluorescence is 
probably due to the exceptionally low amounts of AAG in the LN428WT parental cell line. 
Indeed, the levels of AAG in the LN428WT parental cell line and the XRCC1-KD cell line are 
so low as to preclude noticeable detection by western blot (Fig. 4A). Thus, additional 
expression of AAG leads to a significant increase in the excision of εA and Hx. 
To learn if these observations are generalizable to other AAG substrates, we queried 
whether 1,N6-ethenoadenine (εA) excision by AAG could be facilitated by XRCC1. We 
incubated cell extracts from the glioblastoma cells with a molecular beacon containing εA. 
Similar to the Hx molecular beacon, a time-dependent increase in fluorescence was 
observed following incubation with lysates from LN428WT, XRCC1-KD, AAGOE and 
AAGOE/XRCC1-KD cells. Of the cell lines examined, the AAGOE cells yielded the greatest 
increase in fluorescence and the AAGOE/XRCC1-KD cells yielded a significant (45% at 40 
min) reduction in the kinetics of BER initiation (Fig. 4F). The difference in the observed 
fluorescence between the AAGOE cells and the AAGOE/XRCC1-KD cells indicates that XRCC1 
does indeed facilitate AAG excision of εA. Collectively, these data indicate that XRCC1 is 
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capable of stimulating the AAG-mediated excision of two inflammation-associated base 
lesions, Hx and εA, in vitro. 
 
3.3 Role of XRCC1/AAG in response to NO˙ exposure in human (glioblastoma LN428) cells 
Results from the molecular beacon assay show that XRCC1 can facilitate AAG-
mediated BER of inflammation-induced base lesions in vitro. Given that CHO cells and 
human cells can differ significantly, we set out to measure the impact of XRCC1 on BER 
intermediates in glioma cells, following exposure to MMS and NO˙. Following exposure to 
MMS, we observed a time-dependent increase in BER intermediates for all genotypes 
examined, as measured by comet assay and the observed increase in the tail moment 
following 50 µM MMS exposure (Fig. 5A). Importantly, we found that the LN428WT, XRCC1-
KD, GFP and the AAGOE cells, accumulated similar levels of BER intermediates. This 
indicates that the increase in base-excision initiation that is the result of over expression of 
AAG is tolerated in these cells. Additionally, this result indicates that the deficiency in XRCC1 
is similarly tolerated at these low doses of MMS (50 µM), with respect to the accumulation 
of BER-intermediates. However, when XRCC1 is suppressed in cells that over-express AAG 
(AAGOE/XRCC1-KD cells), there is a significant accumulation of BER intermediates (Fig. 5A). 
The accumulation of BER intermediates in cells that over-express AAG and are deficient in 
XRCC1 (AAGOE/XRCC1-KD) is consistent with a model in which XRCC1 is enhancing AAG 
activity but primarily facilitating the activity of a BER step downstream of the glycosylase. 
Thus AAG initiates BER and excises damaged bases from DNA to form BER intermediates 
that can then be detected by the comet assay, and the lack of XRCC1 prevents the efficient 
resolution of these BER intermediates. We speculate that the lack of XRCC1 results in the 
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decreased efficiency of the 5’-dRP lyase activity of Polß, previously shown to be the rate-
limiting step in the monofunctional glycosylase initiated BER [89-92]. Indeed, it has been 
demonstrated that the XRCC1/Polß interaction is important for the repair of both alkylation 
[44] and oxidative [52] DNA damage.  Thus, the accumulation of BER intermediates in 
AAGOE/XRCC1-KD cells may primarily be due to an accumulation of BER intermediates 
occurring in-between the glycosylase step and the 5’-dRP lyase gap-tailoring step of Polß. 
This result demonstrates the importance of XRCC1 in tolerating an imbalance in BER, caused 
by excess glycosylase activity. Therefore, when considering the potential impact of an 
observed increase in glycosylase activity, the efficiency of downstream components, 
including XRCC1, must be considered. For example, we have demonstrated recently that the 
sensitivity of human cancer cells to chemotherapeutic alkylating agents depends on the 
expression profile of both AAG (MPG) and Polß [59, 93]. 
In order to determine the susceptibility of the human glioblastoma cell lines to killing 
by MMS, we exposed cells to increasing concentrations of MMS, ranging from 0 to 500 µM, 
for 4 hours (the time found to yield a significant difference among these 4 cell lines in the 
comet assay, Fig. 5A) and measured cell survival after 48 hours, as we have described 
previously [58, 59, 93]. We found that both cell lines with elevated expression of AAG 
(AAGOE and AAGOE/XRCC1-KD cells) were significantly more sensitive to MMS than those 
with low (undetectable) expression of AAG (LN428WT and XRCC1-KD cells) (Fig. 5B). The 
XRCC1-KD cells were not more sensitive to killing by MMS than LN428WT cells, likely due to 
the low level of AAG expression in these cells (see Fig. 4A). Consistent with the observation 
that the AAGOE/XRCC1-KD cells displayed highly elevated BER intermediates following 
exposure to MMS (Fig. 5A), the AAGOE/XRCC1-KD cells were more susceptible to killing by 
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MMS than even the AAGOE cells (Fig. 5B). This suggests that the elevated BER intermediates 
observed in AAGOE/XRCC1-KD cells are highly toxic and that the loss of XRCC1 prevents 
downstream processing of these BER intermediates.  
To explore the extent to which XRCC1 can facilitate AAG-initiated base excision of 
NO˙-mediated DNA damage in live cells, we exposed glioblastoma cells to two steady state 
concentrations of ~2µM and ~11µM of NO˙, achieved by exposure to 10% and 100% NO˙, 
respectively. Interestingly, the response of the human glioblastoma cells to NO˙ exposure 
was different from the CHO cell response. Indeed, the glioblastoma cells tolerated the 10% 
NO˙ better than the CHO cells, resulting in only nominal increases in BER-intermediates (Fig. 
6A). This result is consistent with previous findings that different cell types have different 
thresholds for, and thus respond differently to, NO˙ exposures [11, 61, 62]. Similar to the 
MMS exposures, BER intermediates in the XRCC1-KD cells, AAGOE cells and GFP control cells 
exposed to 10% and 100% NO˙ were similar to the levels in the LN428WT cells (Fig. 6A and 
B). In contrast, the AAGOE/XRCC1-KD cells showed higher levels of BER intermediates 
compared to XRCC1-KD cells (Fig. 6C). These data suggest that AAG removes RONS-induced 
base damage, and furthermore reveal that the impact of XRCC1 is dependent on AAG.  
 To learn about the role of XRCC1 in modulating the toxic effects of NO˙, all 
glioblastoma genotypes were challenged with both 10% (Fig. 6D) and 100% (Fig. 6E and F) 
NO˙. Greater toxicity was observed for the 100% NO˙ exposure, and all genotypes were 
found to be sensitive to NO˙ induced toxicity. Furthermore, consistent with the levels of 
BER-intermediates measured in these cells, none of the glioblastoma cells assessed were 
relatively more sensitive to killing by NO˙, when compared to the LN428WT cells (Fig. 6E). 
However, cells that over-express AAG and lack XRCC1 (AAGOE/XRCC1-KD) were significantly 
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more sensitive to NO˙ toxicity than XRCC1 deficient cells (p = 0.04; Fig. 6F). Taken together, 
these results demonstrate that the role of XRCC1 in protecting cells from NO˙-induced 
toxicity is dependent on the levels of AAG. 
 
 
4.0 Conclusions 
 Understanding the role that reactive nitrogen and oxygen play in initiating and 
promoting malignancy is important for risk assessment and therapeutic intervention in 
inflammation-associated malignancies.  Here, we examined a putative risk factor in 
inflammation-associated malignancy: the role of XRCC1 in the repair of DNA damage by the 
reactive nitrogen species ONOO- and NO˙.  We found that in CHO cells, XRCC1 is protective 
against ONOO- mediated toxicity, but this protection was at least partially independent of 
XRCC1’s role in base excision repair. These results suggest that XRCC1 may be modulating 
toxicity in a BER-independent fashion. Indeed, there is evidence that XRCC1 may play a role 
in Ku-independent, non-homologous end joining [94-96], a mechanism for the repair of DNA 
double strand breaks which can result in toxicity and other deleterious phenotypes [97]. 
Additionally there are several lines of evidence that suggest XRCC1 may play a role in 
homologous recombination, another pathway by which DNA DSBs can be repaired. For 
example, Taylor et al. showed that XRCC1 partially co‐localizes with an important 
homologous recombination protein, Rad51, implicating XRCC1 in homologous 
recombination [98]. Further, the high levels of XRCC1 observed in testes relative to levels in 
other cell types [99] and the occurrence of these higher levels specifically in pachytene 
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spermatocytes [100], implicate XRCC1 in meiotic recombination. These examples, and 
indeed our findings here, are consistent with role(s) for XRCC1, in addition to its role in base 
excision repair. 
While we observed that XRCC1 may stimulate AAG excision of the inflammation 
mediated base lesions Hx and εA in vitro, as measured by the Molecular Beacon assay, in 
human glioblastoma cells XRCC1 appears to primarily act downstream of the glycosylase 
when cells are exposed to either NO˙ damage and for alkylation damage.  This is particularly 
striking following exposure of the cells to MMS, where the loss of XRCC1 in the cells with 
elevated expression of AAG (AAGOE/XRCC1-KD) show extreme hypersensitivity to MMS. 
Furthermore, although the XRCC1-KD cells do not show an increase in the levels of NO˙-
induced BER intermediates, the human glioblastoma LN428WT and XRCC1-KD cells express 
almost no AAG, raising the possibility that XRCC1’s role in response to NO˙ is AAG-
dependent. Overexpression of AAG indeed demonstrated a significant rise in BER 
intermediates in the XRCC1-KD cells (AAGOE/XRCC1-KD), indicating that AAG actively 
removes RONS-induced lesions in human cells, and that AAG acts upstream of XRCC1 in 
response to NO˙ and MMS exposure. Likewise, cells expressing high levels of AAG do not 
show a significant increase in the levels of BER intermediates unless XRCC1 is knocked 
down, especially at low doses of MMS. Taken together, the impact of deficiencies in XRCC1, 
such as those caused by polymorphic variants, appears to be dependent on the levels of 
AAG. Given the reports on over-expression of AAG in several cancers [101-104], it is 
suggested that the expression of AAG be considered when evaluating potential functional 
impact of XRCC1 polymorphic variants.  
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Figure Legends 
 
Figure 1. Role of XRCC1 in modulating toxicity of ONOO- and NO˙ in CHO cells. A. XRCC1 WT 
(AA8) and null (EM9) CHO cells, as well as human XRCC1 complemented EM9 (H9T3-6-3 and 
H9T3-7-1) cells were used to assess the toxicity of (B) MMS, (C) the ONOO- donor SIN-1 and 
(D) gaseous NO˙, using a clonogenic survival assay. P values were produced by a two-tailed t-
test and only values below 0.05 are displayed.  
 
Figure 2. Role of XRCC1 in the repair of MMS and SIN-1 mediated DNA damage. Base 
excision repair intermediates measured in CHO cells exposed to (A) MMS and (B) SIN-1. 
Repair kinetics subsequently generated by treating CHO cells at the dose specified (---) for 
(C) MMS and (D) SIN-1. P values were produced by a student’s t-test and only values below 
0.05 are displayed.  
 
Figure 3. Role of XRCC1 in the repair of MMS and NO˙ mediated DNA damage. Base 
excision repair intermediates measured in CHO cells exposed to (A) MMS and (B) NO˙. P 
values were produced by student’s t-test and only values below 0.05 are displayed.  
 
Figure 4. XRCC1 facilitates AAG-mediated NO˙-induced base lesion removal. (A) 
Immunoblot showing expression of AAG (MPG) and XRCC1 protein in wild type (LN428WT), 
AAG over-expressing cells (AAGOE), XRCC1 knockdown cells (XRCC1-KD), and AAG over-
expressing cells with XRCC1 knocked down (AAGOE/XRCC1-KD). (B) Bar graph showing the 
relative protein expression of AAG and XRCC1 in LN428WT, AAGOE, XRCC1-KD and 
AAGOE/XRCC1-KD cells. The immunoblot in (A) was scanned and quantified using NIH Image 
J and the associated analysis software package, normalizing the expression across the four 
cell lines to the AAGOE cells and to the expression of PCNA within each sample. (C-F) 
Fluorescent molecular beacon assay indicating XRCC1 facilitated excision of NO˙-induced 
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base lesions by AAG from DNA double-stranded oligonucleotides containing (C) no lesion, 
(D) an abasic analog THF, (E) hypoxanthine (Hx) or (F) 1,N6-ethenoadenine (εA).  
 
Figure 5. Role of XRCC1 and AAG in human glioblastoma cells following exposure to MMS. 
(A) Base excision repair intermediates, as determined by the Comet Assay, measured in 
human glioblastoma cells following exposure to MMS (0.05mM in media). The % Tail (Y-axis) 
for each cell line is potted as a function of MMS exposure time (hours). P values were 
produced by a student’s t-test and only values below 0.05 are displayed. (B) MMS-induced 
cytotoxicity in LN428WT, AAGOE, XRCC1-KD and AAGOE/XRCC1-KD cells. After treatment (4 
hrs MMS followed by 48 hrs in normal media), viable cells were determined using a 
modified MTT assay. Plots show the % viable cells as compared to untreated (control) cells. 
Means are calculated from six values in each experiment. Results indicate the mean ± S.E. of 
three independent experiments. 
 
Figure 6. Role of XRCC1 and AAG in human glioblastoma cells following exposure to NO˙. 
Base excision repair intermediates in human glioblastoma cells exposed to (A) 10% NO˙, (B) 
100% NO˙ for LN428WT and AAG over-expressing cells (AAGOE) and (C) 100% NO˙ for XRCC1 
deficient (XRCC1-KD) cells and XRCC1 deficient, AAG over-expressing cells (AAGOE/XRCC1-
KD). Asterisk indicates that the average difference for AAGOE/XRCC1-KD versus XRCC1-KD is 
significantly greater than zero (95% CI). Toxicity in human glioblastoma cells following 
exposure to (D) 10% NO˙, (E) 100% NO˙ for LN428WT and AAG over-expressing cells (AAGOE) 
and (F) 100% NO˙ for XRCC1 deficient (XRCC1-KD) cells and XRCC1 deficient, AAG over-
expressing cells (AAGOE/XRCC1-KD). 
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Supplementary Data 
Dataset S1. Dataset S1 contains the mean fluorescence values for each of the Molecular 
Beacon plots shown in Figure 4, as well as the values for the standard error of the mean for 
each. 
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